The overall aim is to identify a role for dysfunctional endothelial CFTR in systemic inflammation and oxidative stress and, importantly, new therapeutic targets to reduce systemic inflammation and oxidative stress in people with CF. Here, CFTR is linked to cystic fibrosis.